This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Obagi Medical Products, Inc. Responds To February 10, 2012 Letter Concerning Its Rights Plan And Corporate Governance Matters

Stocks in this article: OMPI

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, responds to the letter dated February 10, 2012 concerning its Rights Plan and corporate governance matters.

On February 10, 2012, our Board of Directors received a letter related to its Rights Plan and certain corporate governance matters. After due consideration by the Board of Directors, the Company provides the following response.

As provided in our letter to stockholders dated January 10, 2012, the Rights Plan was designed to ensure that all of our stockholders receive fair and equal treatment in the event a stockholder or group of stockholders or other third party attempts to acquire a substantial interest in the Company’s common stock or attempts an unsolicited takeover of the Company. The purpose for adopting the Rights Plan is to encourage any potential acquirer to negotiate with our Board of Directors in good faith, which we believe maximizes value for our stockholders and guards against abusive tactics to gain control of the Company. In addition, as was disclosed in our SEC filings reporting the adoption of the Rights Plan, the Rights Plan will expire on December 23, 2012 unless its adoption is ratified on or prior to such date by our stockholders. As made clear by this expiration date construct, the Board fully intended, and continues to intend, to submit the Rights Plan to our stockholders at this year’s annual meeting for ratification. If our stockholders do not ratify the Rights Plan at this year’s annual meeting, then the Rights Plan will expire pursuant to its terms.

We also believe that it is important to note that our Rights Plan contains the following attributes which are considered best practices by stockholder advisory, risk management and corporate governance bodies:

  • The Rights Plan expires upon the earliest of three years from the date of its adoption, one year from its date of adoption if not submitted to stockholders for ratification and the date of the annual meeting if our stockholders vote against its ratification.
  • The Rights Plan includes a stockholder redemption feature pursuant to which 10 percent of the outstanding shares may call a special meeting to vote on rescinding the Rights Plan if our Board of Directors refuses to redeem the Rights Plan 90 business days after a qualifying offer is announced.
  • The rights will only be exercisable 10 days after it is publicly announced that a person or group (with certain exceptions) has acquired a 20% or greater beneficial ownership stake in the Company’s common stock or 10 business days after a person or group has commenced a tender or exchange offer that would result in the person or group holding a 20% or greater beneficial ownership stake in the Company’s common stock.
  • The Rights Plan does not contain any dead-hand, slow-hand, no-hand or similar feature that limits the ability of a future Board to redeem the rights.

For these reasons, we believe the Rights Plan reaches an appropriate balance between enabling our Board of Directors to use the Rights Plan to maximize stockholder value and the current best practices in corporate governance that give stockholders a voice in such process.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs